Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

The following is a summary of “Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid ...

Cell types detected in the bone marrow of a responder patient pre-treatment (left) and post-treatment (right). Contour lines mark cell groups with similar spatial neighborhoods, highlighting ...

Columbia Engineering and Irving Institute researchers unveil a significant finding in cancer immunotherapy, uncovering unique ...

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, ...

Researchers have identified key factors that determine the success of leukemia cell therapies, including DLI, in achieving ...

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...